PURPOSE: The objective of this research was to provide a comprehensive description of the effect of benazepril on the dynamics of the renin-angiotensin aldosterone system (RAAS) in dogs. METHODS: Blood specimens for renin activity (RA), angiotensin II (AII), and aldosterone (ALD) quantitation in plasma were drawn from 12 healthy adult beagle dogs randomly allocated to 2 treatment groups: (i) benazepril 5 mg PO, q24 h (n: 6) and (ii) placebo (n: 6), in a cross-over design. A mechanism-based pharmacokinetic/pharmacodynamic model, which includes the periodic nature of RA, AII, and ALD during placebo treatment and the subsequent changes in dynamics following repeated dosing with benazepril, was developed. RESULTS: The disposition kinetics of benazepril active metabolite, benazeprilat, was characterized using a saturable binding model to the angiotensin converting enzyme. The modulatory effect of benazeprilat on the RAAS was described using a combination of immediate response models. Our data show that benazepril noticeably influences the dynamics of the renin cascade, resulting in a substantial decrease in AII and ALD, while increasing RA throughout the observation span. CONCLUSIONS: The model provides a quantitative framework for better understanding the effect of ACE inhibition on the dynamics of the systemic RAAS in dogs.
PURPOSE: The objective of this research was to provide a comprehensive description of the effect of benazepril on the dynamics of the renin-angiotensin aldosterone system (RAAS) in dogs. METHODS: Blood specimens for renin activity (RA), angiotensin II (AII), and aldosterone (ALD) quantitation in plasma were drawn from 12 healthy adult beagle dogs randomly allocated to 2 treatment groups: (i) benazepril 5 mg PO, q24 h (n: 6) and (ii) placebo (n: 6), in a cross-over design. A mechanism-based pharmacokinetic/pharmacodynamic model, which includes the periodic nature of RA, AII, and ALD during placebo treatment and the subsequent changes in dynamics following repeated dosing with benazepril, was developed. RESULTS: The disposition kinetics of benazepril active metabolite, benazeprilat, was characterized using a saturable binding model to the angiotensin converting enzyme. The modulatory effect of benazeprilat on the RAAS was described using a combination of immediate response models. Our data show that benazepril noticeably influences the dynamics of the renin cascade, resulting in a substantial decrease in AII and ALD, while increasing RA throughout the observation span. CONCLUSIONS: The model provides a quantitative framework for better understanding the effect of ACE inhibition on the dynamics of the systemic RAAS in dogs.
Authors: C Atkins; J Bonagura; S Ettinger; P Fox; S Gordon; J Haggstrom; R Hamlin; B Keene; V Luis-Fuentes; R Stepien Journal: J Vet Intern Med Date: 2009-09-22 Impact factor: 3.333
Authors: R M A van de Wal; H W M Plokker; D J A Lok; F Boomsma; F A L van der Horst; D J van Veldhuisen; W H van Gilst; A A Voors Journal: Int J Cardiol Date: 2006-01-26 Impact factor: 4.164
Authors: Benjamin Schneider; Violeta Balbas-Martinez; Albert E Jergens; Inaki F Troconiz; Karin Allenspach; Jonathan P Mochel Journal: CPT Pharmacometrics Syst Pharmacol Date: 2017-11-27
Authors: Jessica L Ward; Emilie Guillot; Oliver Domenig; Wendy A Ware; Lingnan Yuan; Jonathan P Mochel Journal: J Vet Intern Med Date: 2022-03-14 Impact factor: 3.175
Authors: Lionel Sebbag; Rachel A Allbaugh; Rita F Wehrman; Lisa K Uhl; Gil Ben-Shlomo; Thomas Chen; Jonathan P Mochel Journal: J Ocul Pharmacol Ther Date: 2019-08-08 Impact factor: 2.671